好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Levetiracetam: Seizure Management for Elderly Patients with Cognitive Impairment
Aging and Dementia
(-)
185
Authors/Disclosures
Carol F. Lippa, MD (Thomas Jefferson University) Dr. Lippa has nothing to disclose.
Gonzalo Revuelta, DO (Medical University of South Carolina) The institution of Dr. Revuelta has received research support from NIH.
G. P. Gliebus, MD, FAAN (Marcus Neurosciences Institute) Dr. Gliebus has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai.
Maureen A. Mealy, PhD, RN No disclosure on file
David Irwin, MD (University of Pennsylvania) The institution of Dr. Irwin has received research support from NIH. The institution of Dr. Irwin has received research support from Prevail. The institution of Dr. Irwin has received research support from Passage Bio. The institution of Dr. Irwin has received research support from Alector. The institution of Dr. Irwin has received research support from Transposon. The institution of Dr. Irwin has received research support from Denali. The institution of Dr. Irwin has received research support from Cervo Med.
No disclosure on file
Andrea L. Rosso, MPH (University of Pittsburgh) No disclosure on file
Farrah J. Mateen, MD, PhD, FAAN (Northwestern University Department of Neurology) Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.